UK Dementia partnership offering £100,000-200,000 awards for dementia research projects
pharmafile | October 23, 2018 | News story | Manufacturing and Production | Alzheimer's, dementia, development, research
The Dementia Discovery Fund (DDF) in partnership with the UK Dementia Research Institute (UK DRI) has announced that it will provide a series of awards between £100,000 and £200,000 to support research projects aimed at developing new medicines for dementia.
Angus Grant, CEO of Dementia Discovery Fund, commented: “Dementia is arguably the greatest single global healthcare challenge, soon affecting 50 million people worldwide at an estimated annual cost to the global economy of approaching a trillion dollars. The DDF continues to work to identify opportunities to invest in and advance innovative science from idea to the clinic. The launch of our new award, in collaboration with the Dementia Research Institute, is a further step in achieving this goal. DDF is ideally positioned to provide scientists with the funding and business support they need to take their projects through development with the potential, if successful, to form new companies in the future.”
Having raised £250 million from an influential group of strategic investors, the DDF has become the first and largest venture fund focused on the discovery and development of novel therapies for dementia.
Bart De Strooper, Director of UK Dementia Research Institute, said: “The UK Dementia Research Institute exists to improve our understanding of dementia and translate this knowledge into treatments and services that will improve lives. This huge task is possible when researchers, charities and for-profit initiatives come together. We are very happy to be working with the Dementia Discovery Fund to launch D3A, an exciting accelerator programme that will move our science closer to the clinic.”
Louis Goss
Related Content
Vesper Bio reports positive topline results for dementia candidate
Vesper Bio, a clinical-stage biotech developing novel oral therapies for neurodegenerative and neuropsychiatric disorders, has …
Lilly’s drug for early Alzheimer’s shows promising results
Eli Lilly (Lilly) has announced positive new data from the long-term extension of its phase …
Mental health medicine use in England reaches record high, NHSBSA report reveals
According to new data published by the NHS Business Services Authority (NHSBSA), mental health prescriptions …
